What is the official website of AbbVie | Virology ?

The official website of AbbVie | Virology is https://www.abbvie.com/our-science/therapeutic-focus-areas/virology.html.

What is AbbVie | Virology's cybersecurity risk score?

AbbVie | Virology has an AI-generated cybersecurity risk score of 754 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has AbbVie | Virology experienced?

According to Rankiteo, AbbVie | Virology currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has AbbVie | Virology been affected by any supply chain cyber incidents ?

According to Rankiteo, AbbVie | Virology has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does AbbVie | Virology have SOC 2 Type 1 certification ?

According to Rankiteo, AbbVie | Virology is not certified under SOC 2 Type 1.

Does AbbVie | Virology have SOC 2 Type 2 certification ?

According to Rankiteo, AbbVie | Virology does not hold a SOC 2 Type 2 certification.

Does AbbVie | Virology comply with GDPR ?

According to Rankiteo, AbbVie | Virology is not listed as GDPR compliant.

Does AbbVie | Virology have PCI DSS certification ?

According to Rankiteo, AbbVie | Virology does not currently maintain PCI DSS compliance.

Does AbbVie | Virology comply with HIPAA ?

According to Rankiteo, AbbVie | Virology is not compliant with HIPAA regulations.

Does AbbVie | Virology have ISO 27001 certification ?

According to Rankiteo,AbbVie | Virology is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does AbbVie | Virology operate in ?

AbbVie | Virology operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does AbbVie | Virology have ?

AbbVie | Virology employs approximately None employees people worldwide.

Does AbbVie | Virology own any subsidiaries ?

AbbVie | Virology presently has no subsidiaries across any sectors.

How many LinkedIn followers does AbbVie | Virology have ?

AbbVie | Virology's official LinkedIn profile has approximately 2,321 followers.

What is the NAICS classification code for AbbVie | Virology ?

AbbVie | Virology is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does AbbVie | Virology have a Crunchbase profile ?

No, AbbVie | Virology does not have a profile on Crunchbase.

Does AbbVie | Virology have a LinkedIn profile ?

Yes, AbbVie | Virology maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/abbvie-virology.

How many cybersecurity incidents has AbbVie | Virology experienced ?

As of September 28, 2026, Rankiteo reports that AbbVie | Virology has experienced 2 cybersecurity incidents.

How many peer or competitor companies does AbbVie | Virology have ?

AbbVie | Virology has an estimated 5,770 peer or competitor companies worldwide.

What types of cybersecurity incidents has AbbVie | Virology faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Vulnerability.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Boost Score +25 with badge (5 left)

754

/1000

Fair

779

/1000

Fair

AbbVie | Virology Vendor Cyber Rating & Cyber Score

abbvie.com

Add Your Compliance Badge

Follow us here on LinkedIn for global news and updates on the work being done to advance the science and understanding of HIV and AbbVie’s HCV elimination efforts. We believe that we all have our own part to play in making HCV elimination the next public health story, and forming transformative partnerships is essential to helping solve some of the most pressing challenges for the HCV community. Review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html

AbbVie | Virology CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

AbbVie

Vulnerability

100

4/2026

EGAABB177565877...

AbbVie | Virology

Breach

100

6/2023

ABB0473723

Loading…

A.I.

AV Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for AV

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for AbbVie | Virology in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for AbbVie | Virology in 2026.

Incident Types AV vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for AbbVie | Virology in 2026.

Incident History - AV (X = Date, Y = Severity)

Loading…

SUBSIDIARY

AbbVie | Virology Subsidiaries

AV

Pharmaceutical Manufacturing

Website: https://www.abbvie.com/our-science/therapeutic-focus-areas/virology.html

Company Size: 10,001+ employees

AbbViePharmaceutical Manufacturing

OncologyPharmaceutical Manufacturing

Allergan AestheticsPharmaceutical Manufacturing

CoolSculptingMedical Equipment Manufacturing

BOTOX® Cosmetic (onabotulinumtoxinA)Pharmaceutical Manufacturing

Allergan Medical InstitutePharmaceutical Manufacturing

Allergan Aesthetics Plastic and Regenerative Medicine PortfolioMedical Equipment Manufacturing

Natrelle Breast ImplantsPharmaceutical Manufacturing

JUVÉDERM® Collection of FillersPharmaceutical Manufacturing

Pharmacyclics, an AbbVie CompanyPharmaceutical Manufacturing

AbbVieEyetoEyePharmaceutical Manufacturing

ImmunologyPharmaceutical Manufacturing

NeurosciencePharmaceutical Manufacturing

Allergan Eye CarePharmaceutical Manufacturing

AbbVieEyetoEyePharmaceutical Manufacturing

Loading…

AbbVie | Virology Similar Companies

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, with 140 years of history, present in 140 countries worldwide, with a turnover of 4.88 billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants and is distributed across six continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Loading…

NEWS

AbbVie | Virology CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

March 08, 2026 08:00 AM

Hackers Allegedly Selling Exploit for Windows Remote Desktop Services 0-Day Flaw

A critical zero-day elevation of privilege vulnerability in Windows Remote Desktop Services (RDS), tracked as CVE-2026-21533, is reportedly...

Read Article

February 20, 2026 08:00 AM

AbbVie Inc. SEC 10-K Report

AbbVie Inc., a global biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of...

Read Article

February 04, 2026 08:00 AM

Cybersecurity & Privacy Group Of The Year: Covington

Covington & Burling LLP helped Papa John's and Bloomingdale's win circuit court appeals in privacy class actions, helped Delta Air Lines...

Read Article

August 22, 2025 02:51 PM

Rachel James, AbbVie: Harnessing AI for corporate cybersecurity

Close-up of a laptop as AI News caught up with Rachel James, Principal. Share this story:.

Read Article

August 11, 2025 07:00 AM

Cencora & The Lash Group Settle Data Breach Litigation for $40 Million

Cencora, The Lash Group, and their affiliates have agreed to pay $40 million to settle class action data breach litigation over a February...

Read Article

July 28, 2025 07:00 AM

Overcoming diagnostic and data privacy challenges in viral disease detection: an integrated approach using generative AI, vision transformers, explainable AI, and federated learning

The growing dependence on artificial intelligence (AI) in healthcare has significantly advanced the detection and diagnosis of viral...

Read Article

March 19, 2025 07:00 AM

Progress from our Frontier Red Team

In this post, we are sharing what we have learned about the trajectory of potential national security risks from frontier AI models.

Read Article

February 28, 2025 05:37 AM

abbv-20241231

AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio.

Read Article

December 24, 2024 08:00 AM

Action likely against AbbVie executive who signed self-declaration

Pharma cos and docs say medical conferences have declined since March after UCPMP was notified.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-96284

SUMMARY

A malicious user can get read-access to files in the flatpak-system-helper context if a system OCI repository is configured, because the OCI code paths in the system helper follow symlinks when importing OCI images that are under the user's control.

Published

Date2026-09-27

Updated

Date2026-09-27

RISK INFORMATION (Score: 2.5)

cvss3

Base Score: 2.5

Complexity: HIGH

CVSS:3.1/AV:L/AC:H/PR:L/UI:N/S:U/C:L/I:N/A:N

Impact Score

1.4

Exploitability

REFERENCES

CVE-2026-100886

SUMMARY

A vulnerability was identified in Seetong T8108, T8108P, T8116 and T8232 4.6.1.4-build202604241011. The affected element is an unknown function of the component Debug Service. Such manipulation leads to improper authentication. The attack may be launched remotely. The exploit is publicly available and might be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-09-27

Updated

Date2026-09-27

RISK INFORMATION (Score: 10)

cvss2

Base Score: 10.0

Complexity: LOW

AV:N/AC:L/Au:N/C:C/I:C/A:C

cvss3

Base Score: 10.0

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

3.9

REFERENCES

CVE-2026-100885

SUMMARY

A vulnerability was found in Krayin laravel-crm up to 2.2.4. This affects an unknown function of the file packages/Webkul/Installer/src/Http/Middleware/CanInstall.php of the component admin-config-setup API Endpoint. The manipulation results in authorization bypass. The attack may be launched remotely. The exploit has been made public and could be used. Upgrading to version 2.2.5 mitigates this issue. The patch is identified as 89f2916b6a46ff91bd1999ce38158fa0de8b9490. Upgrading the affected component is recommended.

Published

Date2026-09-27

Updated

Date2026-09-27

RISK INFORMATION (Score: 7.3)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:P/A:P

cvss3

Base Score: 7.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

3.9

REFERENCES

CVE-2026-100884

SUMMARY

A vulnerability has been found in Krayin laravel-crm up to 2.2.5. The impacted element is the function Storage::download of the file packages/Webkul/Admin/src/Config/acl.php of the component attachment-download Endpoint. The manipulation of the argument ID leads to improper control of resource identifiers. The attack may be initiated remotely. The exploit has been disclosed to the public and may be used. Upgrading to version 2.2.6 is sufficient to resolve this issue. The identifier of the patch is 13d6988cda8d69ece45ee1890effc90a7f21cdc1. It is suggested to upgrade the affected component.

Published

Date2026-09-27

Updated

Date2026-09-27

RISK INFORMATION (Score: 4.3)

cvss2

Base Score: 4.0

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:N/A:N

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.8

REFERENCES

CVE-2026-100883

SUMMARY

A flaw has been found in Krayin laravel-crm up to 2.2.5. The affected element is an unknown function of the file packages/Webkul/Admin/src/Config/acl.php. Executing a manipulation can lead to improper access controls. The attack can be launched remotely. The exploit has been published and may be used. Upgrading to version 2.2.6 is sufficient to fix this issue. This patch is called a399404a388d8ad2700a01349d0d98069c8e85a4. The affected component should be upgraded.

Published

Date2026-09-27

Updated

Date2026-09-27

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

AbbVie | Virology Vendor Cyber Rating & Cyber Score

AV A.I CyberSecurity Scoring

AbbVie | Virology CyberSecurity News & History

AV Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for AV

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types AV vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - AV (X = Date, Y = Severity)

AbbVie | Virology Subsidiaries

AV

AbbVie | Virology Similar Companies

MANKIND PHARMA LTD

UCB

Cipla

MENARINI Group

Novo Nordisk

Zoetis

Sandoz

SUN PHARMA

Alembic Pharmaceuticals Limited

AbbVie | Virology CyberSecurity News

Hackers Allegedly Selling Exploit for Windows Remote Desktop Services 0-Day Flaw

AbbVie Inc. SEC 10-K Report

Cybersecurity & Privacy Group Of The Year: Covington

Rachel James, AbbVie: Harnessing AI for corporate cybersecurity

Cencora & The Lash Group Settle Data Breach Litigation for $40 Million

Overcoming diagnostic and data privacy challenges in viral disease detection: an integrated approach using generative AI, vision transformers, explainable AI, and federated learning

Progress from our Frontier Red Team

abbv-20241231

Action likely against AbbVie executive who signed self-declaration

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

AbbVie | Virology CyberSecurity News & History

AV Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for AV

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types AV vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - AV (X = Date, Y = Severity)

AbbVie | Virology Subsidiaries

AV

AbbVie | Virology Similar Companies

MANKIND PHARMA LTD

UCB

Cipla

MENARINI Group

Novo Nordisk

Zoetis

Sandoz

SUN PHARMA

Alembic Pharmaceuticals Limited

AbbVie | Virology CyberSecurity News

Hackers Allegedly Selling Exploit for Windows Remote Desktop Services 0-Day Flaw

AbbVie Inc. SEC 10-K Report

Cybersecurity & Privacy Group Of The Year: Covington

Rachel James, AbbVie: Harnessing AI for corporate cybersecurity

Cencora & The Lash Group Settle Data Breach Litigation for $40 Million

Overcoming diagnostic and data privacy challenges in viral disease detection: an integrated approach using generative AI, vision transformers, explainable AI, and federated learning

Progress from our Frontier Red Team

abbv-20241231

Action likely against AbbVie executive who signed self-declaration

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo